Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Conditions
Glioblastoma (GBM) · Newly Diagnosed Glioblastoma · GBM · Glioblastoma Multiforme (GBM) · Glioma · Central Nervous System Diseases · Brain Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Highlands Oncology Group, Springdale, Arkansas, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Moffitt Cancer Center, Tampa, Florida, United States
Washington University School of Medicine Siteman Cancer Center, St Louis, Missouri, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Contact: Study coordinator (Oncology Clinical Research Referral Office) · OncologyResearchReferral@hmhn.org · 551-996-1777Atlantic Health, Summit, New Jersey, United States
Contact: Study coordinator (Samantha Caulfield, RN) · Samantha.caulfield@atlantichealth.org · 908-598-6561Northwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success, New York, United States
Contact: Study coordinator (Center for Advanced Medicine - Brain Tumor Center) · neurosurgeryresearch@northwell.edu · 516-253-7753Columbia University Irving Medical Center, New York, New York, United States
Montefiore Medical Center, The Bronx, New York, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Prisma Health, Greenville, South Carolina, United States